Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma

Fig. 3

PCI-24781 does not inhibit HDAC11. A GEPIA on HDAC expression in GBM (Sample size; Control (Black) (n = 207) and GBM (Red) (n = 163)). HDAC1 and 2 are significantly upregulated, while HDAC11 is downregulated (p < 0.01). GEPIA- Gene Expression Profiling Interactive Analysis. B–H HDAC1, HDAC2, and HDAC11 assay were done by Reaction Biology Corp. using fluorogenic peptide from p53 residues 379–382 (RHKK(Ac)AMC) [substrates for HDAC1 and 2] and trifluoroacetyl lysine [substrate for HDAC11]. PCI-24781 and vorinostat inhibit HDAC1 and 2 but do not have an inhibitory effect on HDAC11, as do belinostat and TSA. B, D & F HDAC reference compound TSA were tested in a 10 dose IC50 with 3 fold serial dilution starting at 10 μM (C) HDAC1, (E) HDAC2 and (G) HDAC11. (H) IC50 values are summarized in table.*Empty cells indicate no inhibition or compound activity that could not fit an IC50 curve. TSA-Trichostatin

Back to article page